Information Provided By: 
Fly News Breaks for February 17, 2020
NVS
Feb 17, 2020 | 13:16 EDT
Citi analyst Andrew Baum downgraded Novartis to Neutral from Buy with a CHF 103 price target. The company's ability to fend off generic competition for multiple sclerosis drug Gilenya in the U.S. is now largely priced into the shares, Baum tells investors in a research note. Further, the analyst sees limited near-term upside to his already above consensus estimates.
News For NVS From the Last 2 Days
NVS
Apr 24, 2024 | 12:31 EDT
NVS
Apr 24, 2024 | 11:53 EDT
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
